Source/Disclosures
Source:

Press Release

Disclosures: Jackson reports he is a consultant to Omeros. Walter reports he is a consultant to and speaker for Omeros.
December 04, 2020
1 min read
Save

CMS confirms separate payment for Omidria in ASCs

Source/Disclosures
Source:

Press Release

Disclosures: Jackson reports he is a consultant to Omeros. Walter reports he is a consultant to and speaker for Omeros.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Omidria qualifies for separate payment in ASCs under the CMS policy for non-opioid pain management surgical drugs when used in the ASC setting, according to an Omeros press release.

“I think this is great news as uptake should increase Omidria usage,” Mitchell A. Jackson, MD, told Healio/OSN.

Omidria (phenylephrine 1% and ketorolac 0.3% intraocular solution), approved for use in adults and children, prevents pupil constriction during surgery and reduces postoperative ocular pain.

“It’s a victory for everybody. Patients get better and safer surgery with less pain and less complications. Surgeons have a more predictable and faster surgery. I think this will be the standard for all cases in the OR. I know I will want it for all of my cases whether IFIS, small pupil or not,” Keith A. Walter, MD, told Healio/OSN.

The separate payment status is effective retroactive to Oct. 1, 2020.